Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Langley

Showing results (41-50 of 333) with videos related to

Pageof 34
Sort By:
Innovations in Pharmacy|May 19, 2021
Medicaid Formulary Decisions and the Institute for Clinical and Economic Review: Abandoning Pseudoscience in Imaginary Pharmaceutical Pricing ClaimsPaul C Langley
Innovations in Pharmacy|May 19, 2021
Information or Evidence? Abandoning Imaginary Worlds for Blockchains in Health Technology AssessmentPaul C Langley
Innovations in Pharmacy|May 19, 2021
CVS Health and the Imaginary Worlds of the Institute for Clinical and Economic Review (ICER)Paul C Langley
Innovations in Pharmacy|May 21, 2021
More Unnecessary Imaginary Worlds - Part 1: The Institute for Clinical and Economic Review's Evidence Report on Janus Kinase (JAK) Inhibitors in Rheumatoid ArthritisPaul C Langley
Innovations in Pharmacy|January 11, 2023
Formulary Submissions: Value Claims, Protocols and Outcomes Based Contracting in Rare DiseasePaul C Langley
Innovations in Pharmacy|January 19, 2023
Concerns with Patient Reported Outcome Measurement and Value Claims for Therapy Response: The Case of Mavacamten and Symptomatic Hypertrophic Cardiomyopathy (SHCM)Paul C Langley
Clinical Therapeutics|March 25, 1999
The technology of metered-dose inhalers and treatment costs in asthma: a retrospective study of breath actuation versus traditional press-and-breathe inhalersP C Langley
Clinical Therapeutics|March 1, 1995
Therapy evaluation, patient distribution, and cost-outcomes ratiosP C Langley
Pharmacoeconomics|February 21, 2004
The NICE reference case requirement: implications for drug manufacturers and health systemsPaul C Langley
Clinical Therapeutics|November 1, 1996
Assessing the input costs of disease management programsP C Langley
Pageof 34

Showing results (41-50 of 333) with videos related to

Sort By:
Pageof 34
Innovations in Pharmacy|May 19, 2021
Medicaid Formulary Decisions and the Institute for Clinical and Economic Review: Abandoning Pseudoscience in Imaginary Pharmaceutical Pricing ClaimsPaul C Langley
Innovations in Pharmacy|May 19, 2021
Information or Evidence? Abandoning Imaginary Worlds for Blockchains in Health Technology AssessmentPaul C Langley
Innovations in Pharmacy|May 19, 2021
CVS Health and the Imaginary Worlds of the Institute for Clinical and Economic Review (ICER)Paul C Langley
Innovations in Pharmacy|May 21, 2021
More Unnecessary Imaginary Worlds - Part 1: The Institute for Clinical and Economic Review's Evidence Report on Janus Kinase (JAK) Inhibitors in Rheumatoid ArthritisPaul C Langley
Innovations in Pharmacy|January 11, 2023
Formulary Submissions: Value Claims, Protocols and Outcomes Based Contracting in Rare DiseasePaul C Langley
Innovations in Pharmacy|January 19, 2023
Concerns with Patient Reported Outcome Measurement and Value Claims for Therapy Response: The Case of Mavacamten and Symptomatic Hypertrophic Cardiomyopathy (SHCM)Paul C Langley
Clinical Therapeutics|March 25, 1999
The technology of metered-dose inhalers and treatment costs in asthma: a retrospective study of breath actuation versus traditional press-and-breathe inhalersP C Langley
Clinical Therapeutics|March 1, 1995
Therapy evaluation, patient distribution, and cost-outcomes ratiosP C Langley
Pharmacoeconomics|February 21, 2004
The NICE reference case requirement: implications for drug manufacturers and health systemsPaul C Langley
Clinical Therapeutics|November 1, 1996
Assessing the input costs of disease management programsP C Langley
Pageof 34